LOG ON TO OUR OFFICIAL WEBSITE @ www.indianembassy.ru
 
     
   
  INSIDE THIS ISSUE
   
   
   
  01 MAIN
   
   
  02 NEWSMAKER
   
   
  03 INVESTMENT UPDATE
   
   
  04 TRADE & ECONOMY
   
   
  05 INFOTECH
   
   
  06 FEATURE
   
   
  07 TRAVEL
   
   
  08 CALENDAR
   

   
  HIGHLIGHTS
   
 

Industrial output grows 9.1 pc in Sept
MORE [+]

 
 
Restoration of Lakes
MORE [+]
 
  Meghalaya Timeless Enhancement
MORE [+]
 

 
05 INFOTECH
 
Indian medical devices cos finding space in global arena

Driving through Bangalore’s Whitefield, it’s easy to miss MediVed Innovations’ office tucked away in a corner building. It looks dwarfed by its more glamorous neighbours — the campuses of India’s IT biggies. But there’s something about the work it does that makes the tech revolution pale in comparison.

MediVed’s facilities make pacemakers, which while in existence for years, have been difficult to produce. A pacemaker goes through over 50 processes and is a complex system of wires and polymer components which power the human heart for many years.“The scope for error is zero. A pacemaker just cannot stop working or malfunction else the patient will die,” says Dinesh Puri, chairman, MediVed, which develops active implantable devices and diagnostic devices for cardiac rhythm disorder, a frequent cause of heart attacks. Ask Rita Chakravarty who had to undergo emergency surgery to get a pacemaker fixed in her heart. Her husband had lost his job in the slowdown and she worried about the cost of the operation — Rs.300,000.

“I was taken by surprise when my surgeon told me that the pacemaker would cost around Rs.40,000 only,” she says. That was less than a seventh of what an imported pacemaker would have come for. MediVed is among a clutch of mid-sized Indian companies, which includes Trivitron Healthcare and Opto Circuits, who are taking on global leaders like Johnson & Johnson, Boston Scientific and Hologic, with affordable alternatives to life-saving medical equipment. A mix of backward integration, technological competence and smart acquisitions, is making them tick.

Opto Circuits operates out of Electronic City. This BSE and NYSE listed company has grown to Rs. 8.18 billion in the last decade from Rs. 190 million, making devices like stents and through acquisitions both in India and Europe. Chairman Vinod Ramnani says, “Until now we sold ‘non-invasive’ medical devices like electronic patient monitors and medical sensors that make up three-quarters of our business. But it’s the new ‘invasive’ products line — which includes stents and balloons — that holds promise.” So how have Indian medical device makers managed to crack this tough business? Globally, demand for cardiac pacemakers has been rising.

The U.S. produces half of the world’s medical devices and consumes approximately 40 percent of the world’s output. Indian manufacturers have leveraged cost advantage and class quality at affordable prices. Opto, for instance, makes most of its monitors and sensors at its Indian facilities in Bangalore, Visakhapatnam, Chennai and Himachal Pradesh, where production costs are lower. It also pays zero taxes due to its Export Oriented Units (EOU) status. MediVed hired top class professionals from bigger rivals and also from Indian Space Research Organisation.

“We got the talent to produce the devices, and at the same time regulated the costs,” says Puri. Imports of medical equipment and supplies by India were valued at around $12 billion in 2007. “This can be reduced when domestic products are used,” says Puri, whose company plans to make Rs. 1.5 billion by next year. At present, most of them are looking to capture the lucrative western Europe and U.S markets. And also South East Asia.

Tata Tele switches on high-speed mobile TV

Tata Teleservices (TTSL) today became the first service provider to offer mobile TV on high speed broadband wireless by launching Photon TV, which allows users to access channels on desktops and laptops. The service initially offers 40 channels via a Photon Plus data card (which offers maximum speeds of 3.1 mbps, 20 times faster than what is available on a mobile) covering news, sports, entertainment, children's entertainment and some key regional offerings. In the next three months, the plan is to ramp up the number of channels on offer to 90. Photon TV will allow Tata Photon Plus post-paid users to view a near-live TV feed — there's an eight- to 10-second delay.

Current Photon Plus subscribers will have to download an application to access the service. The company has tied with Apalya Technologies, which aggregates the content and provides it to TTSL. The technology company has agreements with broadcasters on a revenue-share basis. Some mobile service companies like Reliance Communications (which offers 34 channels on the CDMA platforms) also offer mobile TV with a delay of 30 seconds but the quality is limited by the fact that they are on a 2G platform, where speeds are limited to a maximum of 145 kbps. The service, however, is not cheap. The unlimited offer, for instance, leaves little capacity for data usage for normal internet access.

In comparison, a new direct-to-home (DTH) connection at Rs 1,500 plus a six month package of channels free is still cheaper. DTH also allows users to pay only about Rs 250 a month for accessing over 140 channels — though it does not have the advantage of mobility. TTSL so far has half a million users of Photon broadband cards. “We have 40 per cent market share in the data card segment and hope to encash our existing customers to use TV. Also it will enhance data usage,” says chief marketing officer Lloyd Mathias. Competitors have varying opinions on the service. Says Jawahar Goel, managing director of Dish TV, “There is a market for such a service in offices where people do not have access to TV. Only news, business and cricket channels will work in this format, however. Broadcasters, of course, will be happy because they get additional revenue.” TTSL direct competitors say the offer is not attractive.

“Users have to pay a huge bill for using data since the content is data-heavy. We don't think there will be enough customers for such a service,” says a senior executive of a leading telecom company that also sells broadband wireless data cards. Anil Ambani-controlled Reliance Communications, for instance, is tying up with hungama.com to offer music videos on the broadband card that it sells for only Rs 100 a month. Sources say consumers using their data card would be able to access to over 50,000 titles at a nominal price. Meanwhile, broadcasters offering content on the TTSL platform say there are limits to what they can give. Says a senior ESPN executive: “Effectively it can be a tournament or a match but the not the entire channel as available on cable or DTH”.

Indus Biotech to begin HIV drug trials in US

Pune-based Indus Biotech would be starting clinical trials for its HIV botanical drug molecule in the US soon. The company claims this antiviral has also shown promising results for the pandemic H1N1 during initial clinical trials. Indus, founded by Sunil Bhaskaran and Rajan Srinivasan in 1997, is two to three weeks away from completion of the phase-I trials for a botanical drug that the company claims could kill both H1N1 and HIV viruses. Indus is also the first Indian company to have received an Investigational New Drug Number from the US Food and Drug Administration for a botanical anti-viral in HIV research. This permits Indus to conduct further clinical trials related to the drug in the US, the only country in the world that has clear guidelines on botanical drugs. Once the company compiles data from its phase-I study, it would finalise with USFDA the modalities associated with the clinical trials. “Since the area is uncharted territory, we would have to debate the protocol for advanced clinical trials. If the USFDA limits the subject strength to 20-25, we would manage from our company funds. If they ask us to test on 200 to 500 subjects, we would have to raise funds through PE players, fresh or existing or other means,” Srinivasan told FE.

Trials on each subject could cost between $20,000 to $30,000. Two of company’s applications are also being reviewed by DCGI. "Post approval, the clinical trials studies for H1N1 would take five to seven months, while for HIV they would take 18 to 24 months," said Srinivasan. The drug, which the company estimates would cost a fraction of anti-retroviral therapy (ART), the current first-line therapy for AIDS, is expected to hit the market in two years from now. ART costs Rs 20,000 to Rs 25,000 per unit per person annually in India. "However it is difficult to comment on the cost now, which would be decided by the marketing partner to who we outlicense the drug. Once the drug is ready to be commercialised, we would start discussions with companies strong in antivirals and anti-infectives," said Srinivasan. Saying investment in the drug is "significant", he refused to divulge any figures.

UltraTech world's No 10 cement-maker
New Delhi,
Source: HIndustan Times

The board of directors of UltraTech Cement and Samruddhi Cement Limited, a wholly-owned subsidiary of Grasim Industries, on Sunday approved the merger of Samrudhi with UltraTech. The appointed date for the merger is July 1, 2010. Following the merger, UltraTech would become the 10th-largest cement company in the world, with a capacity of 49 million tonnes per annum, and will garner 20 per cent market share in India, a company release said. Samruddhi shareholders will receive four shares of UltraTech for every seven shares held in Samruddhi. On completion of the merger, UltraTech’s expanded equity capital will be held 60.3 per cent by Grasim and 39.7 per cent directly by other shareholders of UltraTech and Samruddhi, the company said. Speaking on the merger, Aditya Birla Group chairman, Kumar Mangalam Birla, said, “The merger will achieve the group’s objective of consolidating its cement business into a single entity, thereby creating a platform that will help in pursuing aggressive growth going forward.” The merged entity will have 504 mega watt captive thermal power plants and 11.7 million cubic meters of ready mix concrete across 68 plants.